Detalhe da pesquisa
1.
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Lancet
; 2024 May 16.
Artigo
Inglês
| MEDLINE | ID: mdl-38763153
2.
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Lancet
; 2024 May 16.
Artigo
Inglês
| MEDLINE | ID: mdl-38763154
3.
Can federal policy help overcome systemically reinforced racial inequities in social determinants of health? An observational study of Georgia and neighboring U.S. states.
BMC Public Health
; 24(1): 304, 2024 01 26.
Artigo
Inglês
| MEDLINE | ID: mdl-38279142
4.
Regional Histopathology and Prostate MRI Positivity: A Secondary Analysis of the PROMIS Trial.
Radiology
; 307(1): e220762, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36511804
5.
Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 23(4): 501-513, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35279270
6.
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
Int J Cancer
; 151(3): 422-434, 2022 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35411939
7.
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
PLoS Med
; 19(6): e1003998, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35671327
8.
Comparison of Transrectal Ultrasound Biopsy to Transperineal Template Mapping Biopsies Stratified by Multiparametric Magnetic Resonance Imaging Score in the PROMIS Trial.
J Urol
; 203(1): 100-107, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31335254
9.
The Emerging Role of Local Therapy in Metastatic Prostate Cancer.
Curr Oncol Rep
; 22(1): 2, 2020 01 20.
Artigo
Inglês
| MEDLINE | ID: mdl-31960153
10.
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(3): 408-419, 2019 03.
Artigo
Inglês
| MEDLINE | ID: mdl-30738780
11.
Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy.
Eur J Nucl Med Mol Imaging
; 46(4): 901-907, 2019 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-30617554
12.
A four-group urine risk classifier for predicting outcomes in patients with prostate cancer.
BJU Int
; 124(4): 609-620, 2019 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-31106513
13.
Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status.
Hum Mol Genet
; 25(24): 5490-5499, 2016 12 15.
Artigo
Inglês
| MEDLINE | ID: mdl-27798103
14.
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.
Lancet
; 389(10071): 815-822, 2017 02 25.
Artigo
Inglês
| MEDLINE | ID: mdl-28110982
15.
National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection - recommendations from a UK consensus meeting.
BJU Int
; 122(1): 13-25, 2018 07.
Artigo
Inglês
| MEDLINE | ID: mdl-29699001
16.
Prostate cancer.
Lancet
; 387(10013): 70-82, 2016 Jan 02.
Artigo
Inglês
| MEDLINE | ID: mdl-26074382
17.
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
BJU Int
; 119(4): 522-529, 2017 04.
Artigo
Inglês
| MEDLINE | ID: mdl-27256016
18.
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Lancet Oncol
; 17(8): 1047-1060, 2016 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-27339115
19.
Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Lancet Oncol
; 16(16): 1605-16, 2015 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-26522334
20.
TE = 32 ms vs TE = 100 ms echo-time (1)H-magnetic resonance spectroscopy in prostate cancer: Tumor metabolite depiction and absolute concentrations in tumors and adjacent tissues.
J Magn Reson Imaging
; 42(4): 1086-93, 2015 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-26258905